| __timestamp | Bristol-Myers Squibb Company | MorphoSys AG |
|---|---|---|
| Wednesday, January 1, 2014 | 3932000000 | 77000 |
| Thursday, January 1, 2015 | 3909000000 | 77000 |
| Friday, January 1, 2016 | 4946000000 | 97000 |
| Sunday, January 1, 2017 | 6066000000 | 33000 |
| Monday, January 1, 2018 | 6547000000 | 1796629 |
| Tuesday, January 1, 2019 | 8078000000 | 12085198 |
| Wednesday, January 1, 2020 | 11773000000 | 9174146 |
| Friday, January 1, 2021 | 9940000000 | 32200000 |
| Saturday, January 1, 2022 | 10137000000 | 48620000 |
| Sunday, January 1, 2023 | 10693000000 | 58355000 |
| Monday, January 1, 2024 | 11949000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. From 2014 to 2023, Bristol-Myers Squibb Company (BMY) and MorphoSys AG (MOR) have shown distinct trajectories in their cost of revenue. Bristol-Myers Squibb, a giant in the sector, saw its cost of revenue grow by approximately 172%, from $3.9 billion in 2014 to over $10.6 billion in 2023. This reflects its expansive operations and increased production costs. In contrast, MorphoSys AG, a smaller player, experienced a staggering increase of over 75,000% in the same period, albeit from a much smaller base, highlighting its rapid growth and scaling efforts. These trends underscore the differing strategies and market positions of these companies, offering valuable insights into their operational efficiencies and market dynamics.
Cost Insights: Breaking Down Novartis AG and Bristol-Myers Squibb Company's Expenses
Cost of Revenue Comparison: Pfizer Inc. vs Bristol-Myers Squibb Company
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and United Therapeutics Corporation
Cost of Revenue Comparison: Bristol-Myers Squibb Company vs Intra-Cellular Therapies, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs MorphoSys AG
Cost of Revenue Comparison: BeiGene, Ltd. vs MorphoSys AG
Cost Insights: Breaking Down Incyte Corporation and MorphoSys AG's Expenses
CRISPR Therapeutics AG vs MorphoSys AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: MorphoSys AG vs Vericel Corporation
MorphoSys AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: MorphoSys AG vs Evotec SE